Travere Therapeutics, Inc.
TVTX
$15.32
-$1.25-7.52%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 74.79M | 62.90M | 54.12M | 41.37M | 45.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.79M | 62.90M | 54.12M | 41.37M | 45.06M |
| Cost of Revenue | 64.62M | 53.31M | 56.39M | 50.92M | 64.31M |
| Gross Profit | 10.17M | 9.59M | -2.28M | -9.55M | -19.25M |
| SG&A Expenses | 69.50M | 65.62M | 64.78M | 64.22M | 63.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.12M | 118.92M | 121.17M | 180.35M | 127.90M |
| Operating Income | -59.33M | -56.03M | -67.05M | -138.98M | -82.84M |
| Income Before Tax | -60.34M | -54.84M | -69.57M | -135.77M | -88.53M |
| Income Tax Expenses | -72.00K | -84.00K | 85.00K | 191.00K | 68.00K |
| Earnings from Continuing Operations | -60.27M | -54.75M | -69.65M | -135.96M | -88.60M |
| Earnings from Discontinued Operations | 4.00K | -59.00K | -757.00K | -103.00K | -1.58M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.26M | -54.81M | -70.41M | -136.06M | -90.17M |
| EBIT | -59.33M | -56.03M | -67.05M | -138.98M | -82.84M |
| EBITDA | -47.24M | -44.79M | -56.71M | -129.10M | -73.35M |
| EPS Basic | -0.73 | -0.70 | -0.91 | -1.76 | -1.18 |
| Normalized Basic EPS | -0.44 | -0.44 | -0.56 | -1.10 | -0.63 |
| EPS Diluted | -0.73 | -0.70 | -0.91 | -1.76 | -1.18 |
| Normalized Diluted EPS | -0.44 | -0.44 | -0.56 | -1.10 | -0.63 |
| Average Basic Shares Outstanding | 83.11M | 77.78M | 77.50M | 77.14M | 76.47M |
| Average Diluted Shares Outstanding | 83.11M | 77.78M | 77.50M | 77.14M | 76.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
